Tibetree Pain Relieveing Medicated Plaster

Camphor


Tibet Cheezheng Tibetan Medicine Co. Ltd
Human Otc Drug
NDC 66506-186
Tibetree Pain Relieveing Medicated Plaster also known as Camphor is a human otc drug labeled by 'Tibet Cheezheng Tibetan Medicine Co. Ltd'. National Drug Code (NDC) number for Tibetree Pain Relieveing Medicated Plaster is 66506-186. This drug is available in dosage form of Plaster. The names of the active, medicinal ingredients in Tibetree Pain Relieveing Medicated Plaster drug includes Camphor (natural) - 1 g/100g . The currest status of Tibetree Pain Relieveing Medicated Plaster drug is Active.

Drug Information:

Drug NDC: 66506-186
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Tibetree Pain Relieveing Medicated Plaster
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Camphor
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Tibet Cheezheng Tibetan Medicine Co. Ltd
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Plaster
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAMPHOR (NATURAL) - 1 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 05 Dec, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 17 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Tibet Cheezheng Tibetan Medicine Co. Ltd
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1725038
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0787654570065
UPC stands for Universal Product Code.
UNII:N20HL7Q941
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
66506-186-015 PACKAGE in 1 PACKAGE (66506-186-01) / 1.2 g in 1 PACKAGE (66506-186-02)05 Dec, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose external analgesic

Product Elements:

Tibetree pain relieveing medicated plaster camphor zanthoxylum bungeanum fruit rind curcuma longa whole carthamus tinctorius flower bud phlomoides rotata whole myricaria paniculata stem oxytropis chiliophylla whole camphor (natural) camphor (natural)

Indications and Usage:

Uses for the temporary relief of minor pain.

Warnings:

Warnings for external use only

Do Not Use:

Warnings for external use only

When Using:

When using this product avoid contact with the eyes do not use more than 2 plasters a day do not use 1 hour before or after bathing

Dosage and Administration:

Directions adults and children 12 years of age and older: remove protective film from the plaster, pour the liquid onto the pad of plaster and apply it to the painful area or acupoint as directed (see figure) use 1 to 2 plasters every 24 hours apply the plaster to the affected area for 4 to 8 hours. do not apply to area with excessive hair. adhesive plaster may hurt skin upon removal. children under 12 years of age: do not use or consult a doctor.

Stop Use:

Stop use and ask a doctor if condition worsens symptoms persist for more than 7 days symptoms clear up and occur again within a few days excessive irritation of the skin develops redness is present

Package Label Principal Display Panel:

Tibetree pdp 1.jpg tibetree pdp inner packageliquid package 2.jpg 33.jpg inner package liquid package

Inner packageliquid package 2.jpg 33.jpg inner package liquid package

Further Questions:

Questions? +1-510-780-9118


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.